TGen supports Arizona Myeloma Network efforts to share knowledge with cancer caregivers, minimizing their stress and improving patient outcomesContinue reading→

Tiny island nation makes big splash in confronting the world’s third leading cause of cancer deathContinue reading→

If you have not been scared enough by Halloween, read this consent decree announcement made by the FDA on November 1 to Philips Healthcare concerning quality control issues with their automatic external defibrillator. Philips had “tricked” industry by consistently providing unsafe defibrillators so the FDA “treated” them to a cease and desist order through a mandate from a federal judge. Under this consent decree, Philips must cease manufacturing until corrective action is taken.Continue reading→

Dr. Fariba Donovan, an infectious diseases research scientist at the University of Arizona College of Medicine – Tucson, receives contract to examine how the failure to diagnose Valley fever impacts patient health, costs and `antimicrobial stewardship’ of this respiratory infection endemic to the U.S. Southwest.Continue reading→

Is It Obesity or Lipedema? UA Researcher Receives Grant To Study Genetic Risk Factors: Yann Klimentidis, PhD, a genetic epidemiologist at the University of Arizona Mel and Enid Zuckerman College of Public Health, has received funding to study the genetic risk factors for developing lipedema, a painful and body disfiguring condition affecting an estimated 11 percent of U.S. adult women.Continue reading→

From his roots as a fair-haired Minnesota farm boy to climbing the ladder of success in big pharma, to blazing a translational academic research path into life-saving therapies, Charles Arntzen has led one extraordinary life in science.   

Continue reading→

The ‘topping-off’ ceremony for the new $165 million University of Arizona Health Sciences Innovation Building signals the advancement of team-based health professions education in the United States. Continue reading→

Project aims to develop a prognostic test to improve prediction of ALS disease progression Continue reading→

More than one-third of study participants in Phase 2 Study were Cord Blood Registry® (CBR®) clients.Continue reading→